We love what we do and we are extremely motivated to work and deliver results. We have fun at work.
We are an open-minded company that is fully committed to open-discussion and out-of-the-box thinking to deliver innovative solutions to partners and customers.
We like to set ambitious goals, strive and achieve them.
We base our strategy on the quality of our solutions. We believe it’s best to do one thing really well than many things just well.
We strongly believe that human relations are crucial for an organization’s success. Hence, we enforce working with honesty, respect and integrity inside the company and with our collaborators and partners.
We recognize collaboration (and cross-discipline collaboration specially) as the appropriate mechanism to build solutions with greater impact. As a result, we are a company that is always looking for win-win collaborations and partnerships with organizations that share our mission and values.
CEO & Co-founder
CSO & Co-founder
CTO & Co-founder
CFO
Senior Engineer
BD Manager
Research scientist
Senior Researcher
Researcher
Software developer
Junior developer
UX manager
Research intern
Software Developer
Junior business developer
Senior Researcher
Have you studied computer science, computer engineering, biofinformatics, computational chemistry or medicinal chemistry?
Are you willing to work in an innovative software company?
Do you enjoy team working, innovation and challenging the status quo?
Are you looking for an industrial PhD degree on computer science or computational chemistry?
Send us your CV and a couple of references to hr[@]pharmacelera.com and join us!
Open positions
We have no open positions at this time. Follow us on Linkedin to be updated on our open job opportunities.
Enric holds a PhD in Computer Engineering from Universitat Politècnica de Catalunya (UPC) and an Executive General Management Program degree from IESE Business School. Enric was a research visitor at the University of Illinois at Urbana Champaign and he worked for 10 years at Intel, where he led international teams from Israel, Germany, the United States and Spain in the fields of High-Performance Computing and Hardware/Software co-design. Enric is a co-author in 25 scientific publications and 20 filed patents and he was co-director of 3 PhD theses. Enric is co-founder and CEO of Pharmacelera.
Javier is a full-time professor at the University of Barcelona (UB), where he leads the Computational Biology and Drug Design (CBDD) research group, and he has a broad expertise in computational chemistry, medicinal chemistry and Computer-Aided Drug Design software. Javier has authored more than 400 publications that have been referenced more than 15,000 times, has an h-index of 72 based on Google Scholar and accumulates 12% of the official references of MOPAC (the open-source QM package).
Enric holds a PhD in Computer Engineering from Universitat Politècnica de Catalunya (UPC), where he obtained the UPC Award for Outstanding PhD Thesis. Enric was a research visitor at the University of California at San Diego. He is a co-founder of Pharmacelera and leads the Research & Development efforts. Prior to that, he worked at Intel in machine learning and hardware acceleration. Enric is a co-author in 14 scientific publications and 17 patents and has been co-director of 1 PhD thesis.
Greta holds a Business degree form Univeristat de Barcelona and Financial Management and Controlling postgraduate courses from UPF Barcelona School of Management. Greta accumulates more than 10 years of experience in finance management positions, focusing the last 6 years in Biotech and SaaS companies.
Oscar holds a PhD in Computational Chemistry from Universitat Ramon Llull (URL) and an MBA degree from the same university. Oscar combines 10 years of experience in molecular modelling in academia and Spanish biotech companies in the fields of antibacterials, metabolic syndrome, and overactive bladder, among others, and 10 years of experience in business development in Europe and Middle East at Kern Pharma, Opko Health and Omnia Molecular. Oscar is co-author in 3 filed small-molecule patents.
Rémy has over 30 years of experience in Sales and Business Development across various industries. He has experience in positioning and selling Computational Chemistry Medicinal Chemistry, ADME, Tox, Biology, Scale-up chemistry products and services. His areas of expertise include Providing effective sales techniques for Products & Services; Developing sales strategies; Nurturing and developing collaborative projects; Scientific Support to sales organisations; Transversal interaction with Product Marketing and R&D teams; Interaction with various customers (researchers from the pharma, biotech, academic and government teams) and Team Management.
He has published several articles in Computational Chemistry, and has co-edited two books (pharmacophores, data mining).
Prior to joining Pharmacelera, Rémy was associated with Jubilant Biosys as Senior Director Business Development for Discovery Services in Europe. Prior to Jubilant Biosys, he was associated with companies like Sai Life Sciences, BioAscent Discovery Ltd, Prestwick Chemicals, Thomson Reuters, Accelrys, etc.
He holds a Pharmacy degree and a Ph.D (Medicinal Chemistry) from Louis Pasteur University, Strasbourg, France.
Obdulia holds a Ph.D. in Computational Chemistry from University Ramon Llull (URL), awarded as Outstanding PhD Thesis. She has a Diploma degree in chemistry (URL) and biochemistry (University of Barcelona). During her PhD, Obdulia was a research visitor at the Goethe University Frankfurt and Sheffield University. She has 20 years of experience in the application of ligand- and structure-based design techniques in drug discovery in academia (Spanish National Cancer Research Centre-CNIO, Center for Applied Medical Research-CIMA) and industrial scenarios (Evotec Toulouse). She is co-author of over 50 peer-reviewed papers and is inventor in 12 international patents.
Javier holds a PhD in Computational Chemistry from Universitat de Barcelona (UB). His thesis was co-directed by Professor Javier Luque and Enric Herrero. Javier accumulates 6 years of experience in computational chemistry and molecular modelling and he has been an active contributor to the development of PharmScreen and PharmQSAR since he joined the company. Javier is co-author in 3 chemistry publications and 1 patent.
Albert holds a Computer Science degree from Universitat Politècnica de Catalunya (UPC), a MSc in Software Engineering from Universitat Oberta de Catalunya (UOC) and a MSc in Computational Engineering and Mathematics from Universitat Rovira i Virgili (URV). Albert accumulates more than 10 years of experience in software development and High-Performance Computing. Albert is co-author in 1 publication.
Fernando holds a PhD degree in Computational Chemistry from Universidad Autónoma de Madrid (UAM) and he did a post-doc in the NMR unit of the San Raffaele Hospital in Milan applying molecular modelling techniques to epigenetic diseases. Fernando accumulates 5 years of experience in business development and product management in technology companies in the area of drug discovery. Fernando is co-author in 7 publications.
Giorgia holds a PhD in Medicinal Chemistry from the University of Bari and a Master Degree in Pharmacy from the same University. Giorgia was a research visitor at the Broad Institute of Harvard and MIT (Cambridge, USA) and did a Post Doc at the Italian Institute of Technology (Genoa, Italy). Giorgia worked 4 years at Charles River Laboratories (Cambridge, UK) dealing with medicinal chemistry, computational chemistry and DMPK. Giorgia is co-author in 3 scientific publications and 1 patent.
Minyi holds a PhD in Chemical Biology from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (SIOC) and she did a post-doc at the University of Barcelona (UB). Minyi accumulates 5 years of experience in the theoretical study and practical application of structure-based drug design. Minyi is co-author in 8 publications.
Lluís holds a Biochemistry Degree from Universitat de les Illes Balears (UIB), an MSc in Biomedical Research from Universitat Pompeu Fabra (UPF) and an MSc in Bioinformatics from Universitat Autònoma de Barcelona (UAB). At Pharmacelera, Lluís is developing his PhD in Computational Chemistry under the direction of Prof. Javier Luque and Dr. Enric Herrero. His research is focused on the study of predictive models for the ligand-receptor interaction based on hydrophobic descriptors. Lluís is co-author in 3 scientific publications.
Ricardo holds a Electrical Engineering degree from Universitat Politècnica de Catalunya (UPC), a MSc in Telecommunications Engineering from UPC and a MSc in Bioinformatics from Universitat Autònoma de Barcelona (UAB). Ricardo has previously worked in the field of quantum computing applied to finance and security. Ricardo is co-author in 1 publication.
Victor is a last-year student of Computer Science degree from the Universitat Politècnica de Catalunya (UPC). At Pharmacelera, Victor has developed his bachelor’s thesis and now works in the backend.
Marina holds a Bachelor’s degree in Multimedia at the Universitat Oberta de Catalunya, moreover she holds studies of photography, video and sound and accumulates more than three years of experience in branding design, user experience design, user interface design and front-end developing in different programming languages.
Brian holds a Chemistry Degree from Universitat Autònoma de Barcelona and a MSc in Bioinformatics from Universitat Pompeu Fabra. He accumulates more than 2 years of experience in molecular simulations and computational chemistry. At Pharmacelera, Brian is developing his PhD in Computational Chemistry under the direction of Dr. Javier Vázquez and Prof. Jana Selent (IMIM). Brian is co-author in 5 scientific publications.
Marc holds a Higher-Level Training Cycle in telecommunications and is finishing a degree of Telematic Engineering from La Salle University. He brings more than six years of experience in Front-End and Back-End development in big Banking applications and e-commerce applications, those companies are among the most important Spanish companies.
Melchor is a graduate biotechnologist (University of Vic-Central University of Catalonia). He holds a PhD in Theoretical and Computational Chemistry from the University of Barcelona plus two MSc in Biophysics and Theoretical and Computational Chemistry from the University of Barcelona and Rovira i Virgili University, respectively. He is experienced in the biotechnology/pharma sector, where he has held management and senior positions in companies such as Mind The Byte and Molomics. He is an expert in the application and development of computational methods at the frontier between chemistry and biology, mainly oriented towards molecule discovery and drug design. He is also engaged in teaching, acting as course instructor in the MSc in Bioinformatics and Biostatistics (Open University of Catalonia / University of Barcelona). He has supervised dozens of MSc theses, as well as a BSc and a PhD thesis. He is co-author of 20+ publications. He also has an entrepreneurial mindset exemplified by the founding of Burua Scientific and the co-founding of ByteKem. He is an independent consultant who at Pharmacelera acts as a senior researcher in computational chemistry and chemoinformatics.
Carol holds a Ph.D. in Chemical Science and Technology from University of Balearic Islands (UIB), awarded as Outstanding PhD Thesis. During her PhD, she was a research visitor at University of Barcelona, Catalan Institute of Chemical Research (Tarragona) and Sheffield University. Carol performed several post-doctoral stays at Masaryk University (Czech Republic), University of Barcelona (UB) and University College London (UCL), in the latest as a Marie Curie Fellow. Now, she is a lecturer professor at the University of Barcelona (UB), joining the Computational Biology and Drug Design (CBDD) research group. She has experience in computational chemistry and drug discovery, with a high expertise in the use of a wide variety of computational techniques. Carol has authored more than 50 peer-reviewed publications that have been referenced more than 2,000 times, and has an h-index of 24 based on Google Scholar.
Woody Sherman holds a Ph.D. in computational chemistry from the Massachusetts Institute of Technology. During graduate school he founded MolySym, an educational technology company focused on designing human-computer interfaces to improve physical science learning. He also worked at Biogen where he applied novel computational methods for antibody affinity optimization, culminating in a patent and publications. He joined Schrödinger in 2004 where he spent more than 12 years developing and applying advanced computational methods used at biotechnology and pharmaceutical companies throughout the world. As vice president and global head of applications sciences at Schrodinger, Woody led many of the breakthrough projects, including Induced Fit Docking, WaterMap, High-Throughput Virtual Screening, Protein Preparation Wizard, and FEP+. Woody is a key opinion leader in molecular simulations, computer-aided drug design and high-performance computing. He has co-authored more than 80 publications in several fields of computational chemistry and drug discovery. Woody is currently the chief scientific officer at Silicon Therapeutics and an adjunct professor in biochemistry and molecular biology at the University of Massachusetts Amherst.
Mariana holds a PhD in Chemistry from Universidad de Santiago de Chile and she later performed post-doc stays at the University of Durham and Universität Konstanz working on Quantum Mechanics. Mariana is an experienced multilingual and multicultural entrepreneur and manager in the software and scientific industries. She accumulates 25 years of experience in Marketing and Business Development in the Life and Materials Science sector in companies such as Accelrys (now DS Biovia), Perkin Elmer, Dotmatics and Collaborative Drug Discovery (CDD). She also serves as advisor and member of the board in several life science companies.
Manel holds a PhD in Medicinal Chemistry and Molecular Modelling from Universitat de Barcelona (UB) and a Master Degree in Organic Chemistry from the same university. Manel accumulates more than 25 years of industrial experience in the fields of molecular modelling, medicinal and organic chemistry and drug discovery. He worked for 22 years in Almirall and he is now the head of Computational Chemistry at AB Science. Manel is co-author in one patent and in 26 scientific publications.
Albert holds a Pharmacy degree from Universitat de Barcelona (UB), an MBA from EADA Business School and a Stanford School of Business and ESADE Business School degree on Corporate Social Responsibility. Albert accumulates 18 years of experience in business development, technology transfer, marketing and entrepreneurship in the areas of biotechnology, medical devices, digital health and drug discovery in Barcelona and Silicon Valley. He has raised more than 10M euros in his different roles and has served as mentor and board member in more than 10 start-ups.
Joan holds a degree in Medicine from Universitat Autònoma de Barcelona (UAB), a Management Degree from IESE Business School, a Business and Finance degree from Harvard Business School and a master’s degree in Biomedicine, Biotechnology and EU Law from UNED. He currently is the Director of Innovation at Hospital Clínic and the Director of Strategy and Innovation at Barcelona Institute for Global Health (ISGlobal). Joan is an internationally recognized person in the healthcare and pharmaceutical sector, working for 10 years as Medical Director at Bayer and 11 years as Director at Novartis.
Albert has over 30 years expertise in the drug discovery and chemical development of anti-infectives and CNS and pain/inflammation modulators. He holds a PhD in chemistry for the Max Planck in Germany. Before founding the start-up Abac Therapeutics where he participated in the raise of 16m€ in a series-A round, he served at Ferrer, Ciba-Geigy and Menarini, where he was co-discoverer of the marketed analgesic Enantyum©. At Ferrer he was co-discoverer of the topic quinolone antibiotic Ozanex© /Xepi©, and the CNS drug Lorediplon© in clinical development for the treatment of transient insomnia. He is the author of over 55 peer reviewed articles and of 35 issued patents and serves as scientific advisor and member of the board in 2 start-ups.
Pau is a private investor in health and real estate companies and at the same time he develops consultancy projects for Adequita, a boutique advisory and venture building firm with international expertise to deliver value creating projects. He has successfully created product portfolios in the area of Consumer Health market, entered and developed new international markets, building value companies through brands. He is an expert in Strategical Marketing and “Open Innovation” processes. Pau has served as CEO of Laboratorios Diafarm more than 20 years, and an as active member in several boards of directors in pharma companies (Bioiberica and Impex Quimica). Before, he held executive positions at Procter&Gamble and PriceWaterhouse.
